Valuation: Cabaletta Bio, Inc.

Capitalization 363M 308M 283M 267M 499M 33.79B 508M 3.33B 1.3B 16.23B 1.36B 1.33B 57.63B P/E ratio 2026 *
-2.03x
P/E ratio 2027 * -2.06x
Enterprise value 276M 234M 216M 204M 380M 25.72B 387M 2.54B 992M 12.35B 1.04B 1.01B 43.87B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day+1.88%
1 week+6.19%
Current month+21.19%
1 month+6.54%
3 months+51.63%
6 months+12.80%
Current year+48.86%
1 week 3.04
Extreme 3.04
3.32
1 month 2.45
Extreme 2.45
3.32
Current year 2
Extreme 2
3.78
1 year 1.06
Extreme 1.06
3.78
3 years 0.99
Extreme 0.9857
26.35
5 years 0.59
Extreme 0.59
26.35
10 years 0.59
Extreme 0.59
26.35
Manager TitleAgeSince
Chief Executive Officer 64 2017-03-31
Director of Finance/CFO 48 2018-12-31
Chief Tech/Sci/R&D Officer 55 2024-05-31
Director TitleAgeSince
Director/Board Member 70 2019-02-18
Chairman 64 2017-03-31
Director/Board Member 64 2018-09-30
Change 5d. change 1-year change 3-years change Capi.($)
+1.88%+6.19%+179.83%-58.26% 363M
+0.43%+5.58%+33.58%+100.91% 51.73B
+0.79%+5.18%+100.62%+24.18% 47.14B
+1.50%-5.91%+115.97%+815.82% 33.11B
+1.77%+9.81%-3.84%-24.10% 24.89B
+0.32%+6.14%+76.13%-30.98% 19.66B
+1.17%+5.22%+44.66%-34.58% 17.86B
+6.60%+6.76%+67.39%+235.54% 16.22B
+4.09%+8.48%-20.21%+1,228.03% 16.17B
+7.69%+7.29%+68.44% - 14.44B
Average +2.61%+3.61%+66.26%+250.73% 24.16B
Weighted average by Cap. +1.92%+3.73%+59.36%+243.02%

Financials

2026 *2027 *
Net sales - -
Net income -191M -162M -149M -141M -262M -17.76B -267M -1.75B -685M -8.53B -716M -701M -30.29B -225M -191M -176M -166M -309M -20.94B -315M -2.06B -808M -10.06B -844M -826M -35.72B
Net Debt -86.68M -73.46M -67.67M -63.88M -119M -8.07B -121M -796M -311M -3.88B -325M -318M -13.77B -147M -124M -114M -108M -202M -13.64B -205M -1.35B -527M -6.55B -550M -538M -23.28B
Logo Cabaletta Bio, Inc.
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Employees
155
Date Price Change Volume
26-04-14 3.260 $ +1.87% 1,442,056
26-04-13 3.200 $ +2.24% 1,493,096
26-04-10 3.130 $ -1.26% 1,180,441
26-04-09 3.170 $ +2.59% 1,899,937
26-04-08 3.090 $ +0.65% 1,429,012
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.260USD
Average target price
13.12USD
Spread / Average Target
+302.61%

Quarterly revenue - Rate of surprise